Found: 13
Select item for more details and to access through your institution.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 25, doi. 10.1002/ajh.21912
- By:
- Publication type:
- Article
Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 4, p. 311, doi. 10.3816/CLM.2009.n.061
- By:
- Publication type:
- Article
Phase I/ II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 3, p. 321, doi. 10.1111/bjh.12129
- By:
- Publication type:
- Article
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 6, p. 727, doi. 10.1111/j.1365-2141.2012.09241.x
- By:
- Publication type:
- Article
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 5, p. 580, doi. 10.1111/j.1365-2141.2011.08884.x
- By:
- Publication type:
- Article
Monoclonal gammopathy of undetermined significance: a consensus statement.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 1, p. 28, doi. 10.1111/j.1365-2141.2010.08207.x
- By:
- Publication type:
- Article
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
- Published in:
- European Journal of Haematology, 2009, v. 82, n. 6, p. 433, doi. 10.1111/j.1600-0609.2009.01244.x
- By:
- Publication type:
- Article
A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 4, p. 336, doi. 10.1016/j.clml.2011.02.002
- By:
- Publication type:
- Article
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
- Published in:
- Supportive Care in Cancer, 2015, v. 23, n. 6, p. 1503, doi. 10.1007/s00520-014-2486-7
- By:
- Publication type:
- Article
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 1, p. 89, doi. 10.1007/s00277-013-1910-2
- By:
- Publication type:
- Article
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
- Published in:
- Annals of Hematology, 2011, v. 90, n. 2, p. 193, doi. 10.1007/s00277-010-1052-8
- By:
- Publication type:
- Article
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
- Published in:
- Annals of Hematology, 2008, v. 87, n. 8, p. 623, doi. 10.1007/s00277-008-0501-0
- By:
- Publication type:
- Article
Using a Powered Bone Marrow Biopsy System Results in Shorter Procedures, Causes Less Residual Pain to Adult Patients, and Yields Larger Specimens.
- Published in:
- Diagnostic Pathology, 2011, v. 6, n. 1, p. 23, doi. 10.1186/1746-1596-6-23
- By:
- Publication type:
- Article